Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20995893 | 0.81 | PPM1B (0.52) | PPM1BPTPN1PPP1CCCYP2C19CHRNB2 | |
| SCHEMBL28287653 | 0.74 | PPM1B (0.60) | PPM1BPTPN1PPP1CCCYP2C19TP53 | |
| SCHEMBL13658097 | 0.73 | PPM1B (0.44) | PPM1BPTPN1PPP1CCCYP2C19CHRNB2 | |
| SCHEMBL24570710 | 0.72 | PPM1B (0.41) | PPM1BPTPN1PPP1CCCYP2C19CHRNB2 | |
| SCHEMBL8498497 | 0.71 | CYP2C19 (0.43) | PPM1BPTPN1PPP1CCCYP2C19MMP2 | |
| SCHEMBL9937926 | 0.69 | PPM1B (0.41) | PPM1BPTPN1PPP1CCCYP2C19MMP2 | |
| SCHEMBL335468 | 0.69 | PPM1B (0.41) | PPM1BPTPN1PPP1CCCYP2C19MMP2 | |
| SCHEMBL9967119 | 0.69 | PPM1B (0.41) | PPM1BPTPN1PPP1CCCYP2C19MMP2 | |
| SCHEMBL394447 | 0.69 | PPM1B (0.41) | PPM1BPTPN1PPP1CCCYP2C19MMP2 | |
| SCHEMBL9967120 | 0.69 | PPM1B (0.41) | PPM1BPTPN1PPP1CCCYP2C19MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11090389-B2 | Mitochondrially targeted PARP inhibitor, and uses thereof | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200038518-A1 | Mitochondrially Targeted PARP Inhibitor, and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038518-A1 | Mitochondrially Targeted PARP Inhibitor, and Uses Thereof | PARP1, PARP2, PARP3 | PPM1B 2960/4885PTPN1 4695/4885PPP1CC 3405/4885 |
| US-11090389-B2 | Mitochondrially targeted PARP inhibitor, and uses thereof | PARP1, PARP2, PARP3 | PPM1B 2960/4885PTPN1 4695/4885PPP1CC 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.